US Patent 9,522,155 (DCA compositions with a synthetic side chain): scope, claim architecture, and US landscape
What does US 9,522,155 claim, in plain scope terms?
US 9,522,155 claims compositions and use claims built around deoxycholic acid (DCA) where DCA has a “synthetic side chain” defined by a formula recited in the specification/claims (your excerpt shows the formula as a placeholder). The independent claim is a composition; the other independent claim is a method of removing fat deposits; and there are device/container claims covering syringes that load the same formulation.
Claim set structure
| Claim |
Claim type |
Core requirement(s) |
Composition parameters called out |
| 1 |
Product (composition) |
DCA at defined level + DCA has synthetic side chain formula + excipient(s)/carrier(s) |
0.1% w/v to 2% w/v DCA |
| 2 |
Use (method) |
Administer therapeutically effective amount of the composition of claim 1 |
Inherits claim 1; dosage tied to “therapeutically effective amount” |
| 3 |
Use (dependent) |
Inherits claim 2 |
Fixes 0.1% w/v to 2% w/v |
| 4 |
Use (dependent) |
Inherits claim 2 |
Adds up to 5% w/v phosphatidylcholine (PC) |
| 5 |
Use (dependent) |
Inherits claim 2 |
Explicitly excludes PC (“does not contain PC”) |
| 6 |
Device (syringe/container) |
Syringe or syringe-loadable container containing the composition; inherits synthetic-side-chain DCA and excipient/carrier concept |
Not limited by DCA wt% in this claim, but constrained by dependent claims |
| 7 |
Device (dependent) |
Inherits claim 6 |
0.1% w/v to 2% w/v DCA |
| 8 |
Device (dependent) |
Inherits claim 6 |
Adds up to 5% w/v PC |
| 9 |
Device (dependent) |
Inherits claim 6 |
Excludes PC (“does not contain PC”) |
Key point for claim-scope analysis: the anchor limitation is not merely “DCA” but “DCA comprising a synthetic side chain of formula [recited]”. That means both composition and method claims are likely to be narrowed to a specific structural variant of DCA, even if the concentration range and excipient/carrier language are broad.
What is the practical claim scope around formulation?
1) Concentration range is explicit (but not the only limitation)
The claimed compositions cover about 0.1% w/v to about 2% w/v DCA (claims 1, 3, 7). This creates a numeric infringement band, subject to “about” tolerances.
2) Excipients/carriers are generic, so the DCA structure drives novelty and most scope
Claims 1 and 6 require “at least one pharmaceutically acceptable excipient and/or carrier.” No further excipient identity is recited in your excerpt. With generic excipient language, design-around using different buffers/solvents may not avoid infringement if the active meets the synthetic-side-chain definition.
3) Phosphatidylcholine (PC) is handled by inclusive and exclusive dependents
Claims 4 and 8 add a formulation option: up to 5% w/v phosphatidylcholine. Claims 5 and 9 add an option: composition does not contain phosphatidylcholine.
Claim interpretation impact: these dependent claims show the patentee anticipated PC as a formulation variable and tried to fence both alternatives inside the same claim family. That tends to reduce the chance that a competitor avoids infringement by simply removing or adding PC within reasonable bounds.
What is the practical claim scope around use (fat deposit removal)?
Claims 2, 3, 4, and 5 cover a method for removal of fat deposits in a mammal by administering a therapeutically effective amount of the claimed formulation.
How broad is the “method” claim?
- It is tied to administration of the same formulation that includes the synthetic-side-chain DCA.
- It is not limited to a specific anatomical site in the excerpt.
- It is not limited to a specific dosing frequency in the excerpt.
- It is not limited to specific patient sub-populations in the excerpt.
Where infringement risk likely sits
If a competitor uses:
1) an injectable formulation with DCA-like bile acid chemistry, but
2) the active does not have the claimed synthetic side chain formula, the method claim may not read.
If a competitor uses:
1) the claimed synthetic-side-chain DCA and
2) administers it in a therapeutically effective amount within the composition constraints,
the method claim is difficult to avoid using “use” changes alone.
What is the practical claim scope around syringes?
Claims 6-9 add formulation-in-container coverage:
- A syringe or syringe-loadable container containing the claimed composition.
- Dependent claims lock in 0.1% w/v to 2% w/v and PC presence/absence options.
Implication: If a product is supplied in prefilled syringes or cartridge-loadable systems, infringement risk rises because the device claims can be asserted even when the manufacturing process or instructions differ.
Where the scope is likely narrowest (and where it is likely broadest)
Narrowest limitation
The synthetic side chain identity is the primary structural gate. Even with generic “DCA,” the claim requires DCA that comprises a synthetic side chain of formula.
Broadest elements
- “At least one pharmaceutically acceptable excipient and/or carrier” (no list is given in the excerpt)
- PC inclusion as “up to 5% w/v”
- “Therapeutically effective amount”
- Device claims cover any syringe or syringe-loadable container
Claim-by-claim landscape mapping (infringement and design-around logic)
Possible infringement pathways
| Competitor product attribute |
Composition claim 1 |
Method claim 2 |
Syringe claim 6 |
| Uses synthetic-side-chain DCA matching the recited formula |
Yes, structural match is required |
Yes, plus effective dosing |
Yes, plus packaging form |
| Uses conventional DCA without the synthetic side chain |
Likely no (fails “DCA comprises synthetic side chain of formula”) |
Likely no |
Likely no |
| Uses synthetic-side-chain DCA but concentration outside 0.1% to 2% |
Likely no (fails concentration) |
Likely no |
Likely no |
| Uses correct active and correct concentration but contains PC >5% |
Claims 4/8 may not apply; claim 1/2/6 could still apply if “at least one excipient” is satisfied and PC limit is not imposed in the independent |
Same |
Same |
| Uses correct active and concentration; excludes PC |
Claims 5/9 support this option |
Claims 2-3 still apply |
Claims 6-7 still apply |
Most effective design-around lever
A credible design-around must address the synthetic side chain formula. Concentration and PC are comparatively easier to adjust, but they are not enough if the active structure is still within the claimed definition.
What does this mean for the US patent landscape?
Without the full patent record details (publication history, priority, cited references, and the complete specification text), a rigorous, claim-level US landscape map cannot be completed from the excerpt alone. The scope implications, however, indicate how the relevant US landscape typically clusters for injectable bile acid therapies:
Landscape cluster 1: bile acid injectable formulations
US patents in this category typically claim:
- bile acid or derivative identity (often with specific substitutions)
- concentration or formulation buffers
- membrane disruption mechanisms and adjuncts (including phosphatidylcholine)
- administration formats (vials, syringes, prefilled injectables)
For this patent, the novelty hinge is the synthetic side chain on DCA. That shifts the landscape from generic “DCA lipolysis” to structure-defined DCA derivatives.
Landscape cluster 2: “mechanism by structure” versus “mechanism by use”
Because the independent use claim is not broadly “use DCA for fat removal” but rather “administer the composition where DCA has the claimed synthetic side chain,” the active structure is the key element. In landscape terms, the most relevant counter-positions will be other US filings that:
- claim different DCA side chains or bile acid substitutions while still supporting fat deposit removal; or
- claim formulation strategies while using the same or closely related DCA derivatives.
Landscape cluster 3: combination formulation around PC
The presence of PC in dependent claims, plus explicit “no PC” dependents, suggests PC is a known variable in the art. The enforceable differentiation in this family likely comes from:
- the specific DCA derivative structure, not PC.
- The PC role is to broaden coverage of formulations that either include or omit PC.
What is the likely enforcement posture of US 9,522,155?
The claim set targets three enforcement vectors that matter in injectable aesthetics:
1) Substance-in-formulation (composition claim 1)
2) Substance-in-use (method claim 2)
3) Substance-in-device packaging (syringe claim 6)
That gives the patentee multiple theories across manufacturing, product supply, and clinical/administrative practice.
Key Takeaways
- The core infringement trigger is structural: the active must be deoxycholic acid with a synthetic side chain defined by the recited formula, not generic DCA.
- Quantitative fence exists: independent and dependent claims require about 0.1% w/v to about 2% w/v DCA (claims 1, 3, 7).
- Phosphatidylcholine is covered on both sides of the formulation line: claims include both up to 5% w/v PC and no PC (claims 4-5, 8-9).
- Enforcement spans product, method, and packaging: composition (1), method (2), and syringe/container (6-9) provide multiple angles for action.
- Design-around likely requires changing the synthetic side chain definition, not just excipients or PC.
FAQs
-
Does claim 1 cover conventional DCA without the synthetic side chain?
No on its face. Claim 1 requires DCA “comprises a synthetic side chain of formula” as recited.
-
If a product uses the claimed derivative but at 0.05% w/v DCA, is it within scope?
No based on the explicit about 0.1% w/v to about 2% w/v limitation in claims 1, 3, and 7.
-
Is phosphatidylcholine optional for infringement?
Yes. The family includes dependents for up to 5% w/v PC and dependents where the composition does not contain PC.
-
Can the method claim be infringed without selling syringes?
Yes, if a party administers the therapeutically effective amount of the claimed formulation for fat deposit removal (claim 2).
-
Does the syringe claim require a specific syringe type?
It requires a syringe or syringe-loadable container containing the claimed composition; dependent claims then add the DCA concentration and PC options.
References
- US Patent No. 9,522,155.
